Dilon to distribute SurgicEye imaging technologies in the U.S.

Justine Varieur Cadet | | Health Imaging | Screening
Dilon Diagnostics, a developer of molecular breast imaging technologies, has become the exclusive U.S. distributor of products from SurgicEye, developer of intraoperative soft tissue imaging and navigation technologies.

The Munich-based SurgicEye said its declipseSPECT / CSS300 provides intraoperative 3D image visualization and navigation for gamma probes during radio-guided surgery. The technology extends commonly used gamma probes and combines imaging and image viewing as a tool to resect radioactively labeled structures like primary breast tumors, metastases and sentinel lymph nodes in a minimally invasive approach. This intraoperative imaging technology contributes to quality assurance and provides evidence for sentinel lymph node and tumor resection during the surgery.

SurgicEye received FDA clearance of its declipseSPECT / CSS300 intraoperative gamma probe 3D visualization device.

 

 

Justine Varieur Cadet

Related Content

AI reduces CT lung cancer screening workload by nearly 80%
Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans

Around the web

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

Cardiovascular Business
Continuation of 99mTc-PYP shortage prompts need for alternative cardiac amyloidosis imaging

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.